99mTc methylene diphosphonate (99mTc MDP) was evaluated as a clinical renal imaging agent in 20 patients referred for bone scintigraphy. Sequential scintigraphy, which was started immediately after injection, yielded blood flow studies of high quality, and subsequent images accurately delineated renal anatomy and excretion in nonazotemic patients. In comparison with delayed images, early images were vastly superior in quality and demonstrated improved target-to-nontarget activity ratios (p<0.001) and improved lesion detectability (p<0.01). Renal imaging performed incidental to bone scintigraphy with MDP can be greatly enhanced by initiating sequential scintigraphy immediately after injection.
|Original language||English (US)|
|Number of pages||4|
|State||Published - 1980|
ASJC Scopus subject areas
- Radiological and Ultrasound Technology